Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 710 record(s)

Req # A-2020-000593

Adverse Drug Reaction (ADR) for botulinum toxin. Report number: E2B_02925013.

Organization: Health Canada

12 page(s)
March 2021

Req # A-2020-000645

Adverse Reaction Reports (AERs). Report numbers: E2B_01554509, E2B_02541883, E2B_02456944, E2B_02693881, E2B_02797230 E2B_03154000, E2B_03157812, E2B_02968298, E2B_02568754.

Organization: Health Canada

117 page(s)
March 2021

Req # A-2020-000676

Adverse Reaction Reports (AERs). Report numbers: E2B_02847499, E2B_03166944, E2B_02888368, E2B_02940849, E2B_02957403, 000422255, E2B_03077510.

Organization: Health Canada

97 page(s)
March 2021

Req # A-2020-000717

Adverse Reaction Reports (AERs) for C1 Esterase Inhibitor. Report numbers: E2B_03054617, E2B_03152224. (AERs) for CUVITRU. Report numbers: 000911226, 000912204, 000912208. (AERs) for GAMMAGARD LIQUID. Report numbers: 000735871, 000736255, 000737035, 000737157, 000737210, 000917178, 000917203. (AERs) for Immunoglobulin. Report numbers: 000737888, E2B_03014108, 000908360, 000909360, 000911105. (AERs) for FEIBA. Report numbers: E2B_03081621, E2B_03132726, E2B_03144818.

Organization: Health Canada

226 page(s)
March 2021

Req # A-2020-000803

Adverse Reaction Reports (AERs). Report numbers: E2B_03076723, 000912767, E2B_03006384, E2B_03206616, E2B_02720850, E2B_03224385.

Organization: Health Canada

67 page(s)
March 2021

Req # A-2020-000811

Adverse Reaction Reports (AERs). Report numbers: 000914955, 000914937, 000916806, 000917031, E2B_03199850, E2B_03226310, E2B_03253116.

Organization: Health Canada

73 page(s)
March 2021

Req # A-2020-000854

Adverse Reaction Reports (AERs). Report numbers: E2B_03186049, E2B_03186050, E2B_03192501, E2B_03193214.

Organization: Health Canada

38 page(s)
March 2021

Req # A-2020-000858

Adverse Reaction Reports (AERs). Report numbers: E2B_03146211, E2B_02894191, E2B_02196126, 000712016, E2B_01728270, E2B_02224950, E2B_02299168, E2B_02553170, 000716624, 000716626.

Organization: Health Canada

237 page(s)
March 2021

Req # A-2020-000889

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-110509-318, Laboratories Canada Overview.

Organization: Health Canada

17 page(s)
March 2021

Req # A-2020-000898

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-110420-68.

Organization: Health Canada

8 page(s)
March 2021
Date modified: